<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The introduction of <z:chebi fb="0" ids="45783">imatinib</z:chebi> has been a major advance in the treatment of <z:hpo ids='HP_0100723'>gastrointestinal stromal tumor</z:hpo> (<z:hpo ids='HP_0100723'>GIST</z:hpo>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, despite its remarkable efficacy and toxicity profile little is known about the potential for long-term toxicity </plain></SENT>
<SENT sid="2" pm="."><plain>This may be an important issue because some patients (pts) with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) develop, during <z:chebi fb="0" ids="45783">imatinib</z:chebi> treatment, chromosomal abnormalities in philadelphia chromosome (Ph) negative cells with evolution to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), furthermore a nonrandom association between <z:hpo ids='HP_0100723'>GIST</z:hpo> and myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> has been recently reported </plain></SENT>
<SENT sid="3" pm="."><plain>We report here a case of refractory cytopenia with mutilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>) with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 which rapidly transformed into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in a patient with <z:hpo ids='HP_0100723'>GIST</z:hpo> during <z:chebi fb="0" ids="45783">imatinib</z:chebi> treatment </plain></SENT>
</text></document>